Literature DB >> 25989932

Non-hyperfunctioning pancreatic endocrine tumors: multimodality imaging features with histopathological correlation.

Peter E Humphrey1,2, Francesco Alessandrino3, Andrew M Bellizzi4,5, Koenraad J Mortele6,7.   

Abstract

PURPOSE: To evaluate the multimodality imaging features of non-hyperfunctioning pancreatic endocrine tumors (NF-PNET) with histopathological correlation.
METHODS: Preoperative imaging (CT: n = 23; MRI: n = 14; (111)In-octreotide: n = 8) of 28 patients (17 female; mean age 55 years) with resected NF-PNET were evaluated for tumor location, size, morphology, attenuation/signal intensity, (111)In-octreotide uptake, cystic degeneration, and enhancement. Tissue specimens were assessed for the extent of stromal fibrosis, vascular density, presence of a fibrous pseudocapsule, and tumor grading. Correlation between imaging and histopathology was made using the Fisher-Freeman-Halton exact test.
RESULTS: NF-PNET arose from the pancreatic head/neck (n = 10), body (n = 7), and tail (n = 11). On CT, NF-PNET (mean largest diameter: 4.4 cm) appeared predominantly solid (69.6%), well defined (91.3%), and oval (47.8%) in shape. In the late arterial phase, NF-PNET appeared mainly hypovascular (55.5%). Septations (30.4%) and calcifications (21.7%) were relatively uncommon. On MRI, NF-PNET (mean size: 2.6 cm) appeared most commonly as solid (57.1%), encapsulated (71.4%), oval (64.2%) lesions that were hyperintense on T2-WI (64.3%), and hypo- or isovascular to pancreas (66.7%) during the late arterial phase. Cystic NF-PNET (3.8 cm) were not significantly larger than solid (3.5 cm) NF-PNET (CT, p = 0.758; MRI, p = 0.451). (111)In-octreotide uptake was demonstrated in 5/8 (62.5%) patients. At histopathology, NF-PNET were predominantly encapsulated (69.2%); stromal fibrosis comprised <33% of the tumor (69.2%), and vascular density was average (46.1%). A significant association was demonstrated between the degree of fibrosis and hypointensity on T2-WI (p = 0.003). Vascular density, tumor grade, and degree of fibrosis did not significantly relate to the pattern of enhancement.
CONCLUSIONS: NF-PNETs have variable imaging appearances but are most commonly oval shaped, solid, and well-defined/encapsulated masses, and hypovascular on late arterial and portal venous phase. Cystic degeneration in NF-PNET appears independent of tumor size. Low signal intensity on T2-WI correlates with extensive intratumoral fibrosis.

Entities:  

Keywords:  Magnetic resonance imaging; Multidetector computed tomography; Neuroendocrine tumors; Non–hyperfunctioning neuroendocrine tumors; Pancreas; Somatostatin receptor scintigraphy

Mesh:

Substances:

Year:  2015        PMID: 25989932     DOI: 10.1007/s00261-015-0458-0

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  11 in total

1.  Enhancing pancreatic mass with normal serum CA19-9: key MDCT features to characterize pancreatic neuroendocrine tumours from its mimics.

Authors:  Liang Zhu; Hua-Dan Xue; Wei Liu; Xuan Wang; Xin Sui; Qin Wang; Daming Zhang; Ping Li; Zheng-Yu Jin
Journal:  Radiol Med       Date:  2017-02-15       Impact factor: 3.469

2.  Neuroendocrine neoplasm of pancreas with cystic degeneration mimicking mucinous cystic neoplasm.

Authors:  Uayporn Kaosombatwattana; Yoshiki Hirooka; Hiroki Kawashima; Eizaburo Ohno; Takuya Ishikawa; Hiroki Suhara; Hidemi Goto
Journal:  Clin J Gastroenterol       Date:  2018-03-13

3.  Contour variations of the body and tail of the pancreas: evaluation with MDCT.

Authors:  Ahmad Khalid Omeri; Shunro Matsumoto; Maki Kiyonaga; Ryo Takaji; Yasunari Yamada; Kazuhisa Kosen; Hiromu Mori; Hidetoshi Miyake
Journal:  Jpn J Radiol       Date:  2017-04-03       Impact factor: 2.374

4.  68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours.

Authors:  P Mapelli; C Bezzi; D Palumbo; C Canevari; S Ghezzo; A M Samanes Gajate; B Catalfamo; A Messina; L Presotto; A Guarnaccia; V Bettinardi; F Muffatti; V Andreasi; M Schiavo Lena; L Gianolli; S Partelli; M Falconi; P Scifo; F De Cobelli; M Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-14       Impact factor: 10.057

5.  Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance.

Authors:  Chuan-Gen Guo; Shuai Ren; Xiao Chen; Qi-Dong Wang; Wen-Bo Xiao; Jing-Feng Zhang; Shao-Feng Duan; Zhong-Qiu Wang
Journal:  Cancer Manag Res       Date:  2019-03-04       Impact factor: 3.989

6.  Differentiation between non-hypervascular pancreatic neuroendocrine tumour and pancreatic ductal adenocarcinoma on dynamic computed tomography and non-enhanced magnetic resonance imaging.

Authors:  Kazuyoshi Ohki; Takao Igarashi; Hirokazu Ashida; Megumi Shiraishi; Yosuke Nozawa; Hiroya Ojiri
Journal:  Pol J Radiol       Date:  2019-03-13

7.  Differentiating pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas by the "Duct-Road Sign": A preliminary magnetic resonance imaging study.

Authors:  Bo Xiao; Zhi-Qiong Jiang; Jin-Xiang Hu; Xiao-Ming Zhang; Hai-Bo Xu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

8.  Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study.

Authors:  Koichiro Kimura; Junichi Tsuchiya; Yoshio Kitazume; Mitsuhiro Kishino; Keiichi Akahoshi; Atsushi Kudo; Shinji Tanaka; Minoru Tanabe; Ukihide Tateishi
Journal:  Diagnostics (Basel)       Date:  2020-11-09

9.  Total Pancreatectomy for Multicentric Cystic Neuroendocrine Tumor of the Pancreas: A Case Report.

Authors:  Milica Mitrovic-Jovanovic; Nikica Grubor; Stefan Milosevic; Aleksandra Jankovic; Katarina Stosic; Slavenko Ostojic; Aleksandar Ninic; Marjan Micev; Jelena Djokic Kovac
Journal:  Diagnostics (Basel)       Date:  2022-04-15

10.  Unusual Case of a Pancreatic Neuroendocrine Tumor Containing a Central Scar.

Authors:  Binit Sureka; Vaibhav Varshney; Poonam Elhence; Jyotsna Bharti; Taruna Yadav; Pawan Kumar Garg; Pushpinder Singh Khera
Journal:  ACG Case Rep J       Date:  2019-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.